By creating a free Inderes account, you get access to Inderes analysis, you can order the popular morning review and follow companies and discussions that interest you.
Already have an account?
Follow this company like 8554 other investors.
Pihlajalinna’s profitability challenges continued to be way worse in Q4 than estimated. The company has many tools to address the issue.
Pihlajalinna’s Q4 report was a clear disappointment in terms of profitability even after the guidance downgrade late last year.
Pihlajalinna reports Q4 results on Feb 17. Last year thecompany positioned itself for growth, while this year focusrests more on profitability enhancing initiatives.
Pihlajalinna’s Q3 ramp-up costs were larger than expected, but Q4 should already show a clear y/y EBITA improvement.
Pihlajalinna’s Q3 revenue landed close to estimates, whereas profitability came in on the soft side. In our view the roughly EUR 2m miss in profitability could be at least partly attributable to capacity ramp-up costs.
Pihlajalinna reports Q3 results on Nov 4. We still expect Q3 EBITA to have remained a bit muted, but Q4 should see earnings growth while multiples and margins imply upside.
Pihlajalinna’s Q2 didn’t deliver many surprises; we expect further improvement to materialize over the course of H2.
Pihlajalinna’s Q2 results came in largely according to expectations. Top line growth continued strong and certain cost items remained high.
Pihlajalinna reports Q2 results on Fri, Aug 12. Q2 earnings will remain modest due to the integration process and a couple of other cost issues highlighted in the Q1 report.
The Q1 results and notes on Pohjola Hospital support the view Pihlajalinna is advancing in terms of profitability.